RegrowProtocol

Trial pipeline · NCT05456087

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

Phase 2 Active, not recruiting status last verified 2024-03

A registered clinical trial, reproduced from its ClinicalTrials.gov record. Every value on this page is a field on that record. Nothing on this page is a finding, an assessment or a recommendation.

The registered record

Accession number
NCT05456087
Lead sponsor
Zel Skin and Laser Specialists (other)
Collaborators
Merz Aesthetics Inc.
Registered condition naming hair loss
Androgenetic Alopecia

Interventions

  • Drugincobotulinumtoxin A

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type
interventional
Phase
Phase 2
Allocation
na
Masking
none
Primary purpose
treatment
Enrolment
20 participants (actual)
Sites
1 location in United States

What it measures

  1. Changes from baseline in hair count per cm2 (number of hairs per follicular unit)

    Time frame: Day 30, Day 90, Day 180, and Day 270

  2. Changes from baseline in sum of hair width per cm2 (total scalp coverage)

    Time frame: Day 30, Day 90, Day 180, and Day 270

  3. Changes from baseline in Terminal:Vellus ratio (number of terminal hairs for every one vellus hair).

    Time frame: Day 30, Day 90, Day 180, and Day 270

  4. Changes from baseline in Average hairs per follicular unit (average number of hairs within a hair follicle).

    Time frame: Day 30, Day 90, Day 180, and Day 270

  5. Changes from baseline in Average hair width (microns) (average thickness of hair in microns).

    Time frame: Day 30, Day 90, Day 180, and Day 270

  6. Changes from baseline in Follicle count per cm2 (number of follicles per square centimeter).

    Time frame: Day 30, Day 90, Day 180, and Day 270

  7. Mean Inter-follicular distance (mm) (mean distance between follicular units).

    Time frame: Day 30, Day 90, Day 180, and Day 270

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex
all
Age
22 Years to 55 Years
Healthy volunteers
not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start
12 August 2022 (actual)
Primary completion
December 2024 (estimated)
Study completion
December 2024 (estimated)
First posted
13 July 2022 (actual)
Last update posted
27 March 2024 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2024-12 is a month, and rendering it as 1 December 2024 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Androgenetic Alopecia: Complete GuideNew Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually ShowComplete Guide to Finasteride for Hair LossMinoxidil 5% Complete Guide: How to Apply for Best Results

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT05456087 on ClinicalTrials.gov · All 157 trials in the pipeline